Precision dosing of clozapine: A physiologically based pharmacokinetic/pharmacodynamic model integrating genetic polymorphisms and clinical outcomes.

BACKGROUND

The efficacy of clozapine in treatment-resistant schizophrenia is limited by significant pharmacokinetic variability due to genetic polymorphisms, drug interactions, and environmental factors, necessitating personalized dosing strategies.

AIMS: This study aimed at developing a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model integrating genetics and clinical factors to guide precision dosing of clozapine.

METHODS

A simulation study was conducted to develop a PBPK/PD model using R (mrgsolve) to simulate clozapine plasma and brain concentrations, multireceptor occupancies, clinical efficacy, and safety risks (agranulocytosis, seizures, cardiotoxicity). The model incorporated multiple genetic profiles (CYP1A2, CYP2D6, and ABCB1), drug interactions (with fluvoxamine and carbamazepine), smoking effects, and ethnic-specific adjustments. Simulations evaluated steady-state outcomes, therapeutic drug monitoring (TDM) protocols, and optimal dosing. Validation used literature datasets, with sensitivity analyses assessing enzyme activity impacts.

RESULTS

The model demonstrated high predictive accuracy, with simulations revealing substantial variability in clozapine concentrations, primarily driven by CYP1A2 polymorphisms. Model-informed genotype-guided dosing achieved therapeutic levels, markedly improving clinical response and significantly reducing adverse events. Fluvoxamine posed high-risk interactions, particularly in poor metabolizers, while smoking reduced concentrations, requiring dose adjustments. Ethnic-specific dosing addressed population variability, with tailored recommendations for special populations (elderly, pediatric). Sensitivity analyses identified glutathione status as a key determinant in agranulocytosis risk, underscoring the importance of genetic polymorphisms in glutathione S-transferases (GSTT1 and GSTM1) in safety outcomes.

CONCLUSIONS

This PBPK/PD model provides a robust framework for precision clozapine therapy, supporting genotype-guided dosing and TDM to optimize efficacy and safety. The implementation of pharmacogenetic testing could transform clinical practice, offering a framework for optimized resource utilization and risk minimization.